| First Author | Zhong J | Year | 2023 |
| Journal | Nat Commun | Volume | 14 |
| Issue | 1 | Pages | 5451 |
| PubMed ID | 37673856 | Mgi Jnum | J:340553 |
| Mgi Id | MGI:7527868 | Doi | 10.1038/s41467-023-41061-8 |
| Citation | Zhong J, et al. (2023) Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARalpha nucleus-cytoplasm shuttling. Nat Commun 14(1):5451 |
| abstractText | Nonalcoholic fatty liver disease (NAFLD) is usually characterized with disrupted bile acid (BA) homeostasis. However, the exact role of certain BA in NAFLD is poorly understood. Here we show levels of serum hyodeoxycholic acid (HDCA) decrease in both NAFLD patients and mice, as well as in liver and intestinal contents of NAFLD mice compared to their healthy counterparts. Serum HDCA is also inversely correlated with NAFLD severity. Dietary HDCA supplementation ameliorates diet-induced NAFLD in male wild type mice by activating fatty acid oxidation in hepatic peroxisome proliferator-activated receptor alpha (PPARalpha)-dependent way because the anti-NAFLD effect of HDCA is abolished in hepatocyte-specific Pparalpha knockout mice. Mechanistically, HDCA facilitates nuclear localization of PPARalpha by directly interacting with RAN protein. This interaction disrupts the formation of RAN/CRM1/PPARalpha nucleus-cytoplasm shuttling heterotrimer. Our results demonstrate the therapeutic potential of HDCA for NAFLD and provide new insights of BAs on regulating fatty acid metabolism. |
